CEO Jonathan Javitt (NeuroRx)
NeuroRx chief lines up Hail Mary for once-rejected Covid-19 drug
NeuroRx’s Covid-19 treatment was already shot down by the FDA once, and it failed the primary endpoint in a Phase IIb/III readout — but that won …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
